Literature DB >> 9427703

Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that modulates integrin-dependent adhesion and aggregation of human platelets.

D Varon1, D E Jackson, B Shenkman, R Dardik, I Tamarin, N Savion, P J Newman.   

Abstract

Platelet/endothelial cell adhesion molecule-1 (PECAM-1) is a 130-kD member of the Ig gene superfamily that is expressed on the surface of circulating platelets, monocytes, neutrophils, and selective T-cell subsets. It is also a major component of the endothelial cell intercellular junction. Previous studies have shown that cross-linking PECAM-1 on the surface of leukocytes results in the activation of adhesion molecules of both the beta 1 and beta 2 integrin family. In addition, the process of leukocyte transendothelial migration appears to be mediated, at least in part, by homophilic adhesive interactions that take place between leukocyte and endothelial cell junctional PECAM-1 molecules. However, little is known about the functional role of this membrane glycoprotein in human platelets. In the present study, we examined the effects of PECAM-1 engagement on integrin-mediated platelet-extracellular matrix or platelet-platelet interactions. Bivalent, but not monovalent, anti-PECAM-1 monoclonal antibodies (MoAbs) specific for membrane-proximal Ig-homology domain 6 significantly augmented platelet deposition (increased surface coverage) and aggregation (increased average size) onto extracellular matrix, under both oscillatory or defined low shear flow conditions (200 s-1) in a modified cone and plate viscometer. Moreover, bivalent anti-domain 6 MoAbs were capable of serving as costimulatory agonists to markedly enhance both adenosine diphosphate (ADP)- and platelet activating factor (PAF)-induced platelet aggregation resonses. These antibodies appeared to act via outside-in signal transduction through PECAM-1, as evidenced by the fact that their binding (1) led to conformational changes in the alpha IIb beta 3 integrin complex, (2) induced surface expression of P-selectin, and (3) resulted in the tyrosine phosphorylation of PECAM-1. Together, these data support a role for PECAM-1 in cellular activation and suggest that PECAM-1 may serve as a costimulatory agonist receptor capable of modulating integrin function in human platelets during adhesion and aggregation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427703

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  YAP Controls Endothelial Activation and Vascular Inflammation Through TRAF6.

Authors:  Yang Lv; Kyungho Kim; Yue Sheng; Jaehyung Cho; Zhijian Qian; You-Yang Zhao; Gang Hu; Duojia Pan; Asrar B Malik; Guochang Hu
Journal:  Circ Res       Date:  2018-05-23       Impact factor: 17.367

2.  An alternatively spliced isoform of PECAM-1 is expressed at high levels in human and murine tissues, and suggests a novel role for the C-terminus of PECAM-1 in cytoprotective signaling.

Authors:  Carmen Bergom; Cathy Paddock; Cunji Gao; Trudy Holyst; Debra K Newman; Peter J Newman
Journal:  J Cell Sci       Date:  2008-04-15       Impact factor: 5.285

3.  Switched at birth: a new family for PECAM-1.

Authors:  P J Newman
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

4.  Relative contribution of PECAM-1 adhesion and signaling to the maintenance of vascular integrity.

Authors:  Jamie R Privratsky; Cathy M Paddock; Oliver Florey; Debra K Newman; William A Muller; Peter J Newman
Journal:  J Cell Sci       Date:  2011-04-12       Impact factor: 5.285

5.  pp60c-src associates with the SH2-containing inositol-5-phosphatase SHIP1 and is involved in its tyrosine phosphorylation downstream of alphaIIbbeta3 integrin in human platelets.

Authors:  S Giuriato; S Bodin; C Erneux; R Woscholski; M Plantavid; H Chap; B Payrastre
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

6.  Platelet PECAM-1 inhibits thrombus formation in vivo.

Authors:  Shahrokh Falati; Sonali Patil; Peter L Gross; Michelle Stapleton; Glenn Merrill-Skoloff; Natasha E Barrett; Katherine L Pixton; Harmut Weiler; Brian Cooley; Debra K Newman; Peter J Newman; Barbara C Furie; Bruce Furie; Jonathan M Gibbins
Journal:  Blood       Date:  2005-09-15       Impact factor: 22.113

7.  Regulation of endothelial cell barrier function by antibody-driven affinity modulation of platelet endothelial cell adhesion molecule-1 (PECAM-1).

Authors:  Heng Mei; Jay M Campbell; Cathy M Paddock; Panida Lertkiatmongkol; Michael W Mosesson; Ralph Albrecht; Peter J Newman
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

8.  Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.

Authors:  Sylvia T Singer; Frans Kuypers; Jeffery Fineman; Ginny Gildengorin; Sandra Larkin; Nancy Sweeters; Howard Rosenfeld; Gregory Kurio; Annie Higa; Michael Jeng; James Huang; Elliott P Vichinsky
Journal:  Ann Hematol       Date:  2014-02-28       Impact factor: 3.673

9.  PECAM-1 isoform-specific functions in PECAM-1-deficient brain microvascular endothelial cells.

Authors:  Terri A DiMaio; Nader Sheibani
Journal:  Microvasc Res       Date:  2007-10-17       Impact factor: 3.514

10.  PECAM-1 expression and activity negatively regulate multiple platelet signaling pathways.

Authors:  Chris I Jones; Stephen F Garner; Leonardo A Moraes; William J Kaiser; Angela Rankin; Willem H Ouwehand; Alison H Goodall; Jonathan M Gibbins
Journal:  FEBS Lett       Date:  2009-10-20       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.